The global chimeric antigen receptor (CAR) T-cell therapy market garnered a market value of US$ 2.54 billion in 2022. The market is expected to accumulate a market value of US$ 3.5 billion by 2023, and will eventually reach US$ 6.82 billion by registering a CAGR of 6.9% in the forecast period 2023 to 2033. The growth of the chimeric antigen receptor (CAR) T-Cell therapy market can be attributed to technological advancements and demand for personalized medicines. The market for chimeric antigen receptor (CAR) T-Cell therapy registered a CAGR of 7% in the historical period 2018 to 2022.
Chimeric Antigen Receptor (CAR) T-cell therapy is a type of cancer treatment that uses a patient's own immune system to fight cancer. It is a type of immunotherapy that involves modifying a patient's T cells (a type of white blood cell) to recognize and attack cancer cells.
The CAR T-cell therapy process involves collecting a patient's T cells, genetically modifying them to express a CAR on their surface, and then reinfusing the modified cells back into the patient's bloodstream. The CAR is designed to recognize and bind to a specific protein on the surface of cancer cells, which triggers the T cells to attack and destroy the cancer cells.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 3.5 billion |
| Anticipated Forecast Value (2033) | US$ 6.82 billion |
| Projected Growth Rate (2023 to 2033) | 6.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Chimeric antigen receptor (CAR) T-Cell therapy reflected a value CAGR of 7% during the historical period, 2018 to 2022. The growth of the market can be attributed to several factors, including the increasing prevalence of cancer, the growing demand for personalized and targeted therapies, and the increasing investments in research and development of CAR T-cell therapies. In addition, the approval of several CAR T-cell therapies by regulatory agencies, such as the US FDA, has also boosted market growth.
Several companies are actively involved in the development and commercialization of CAR T-cell therapies, including Novartis, Gilead Sciences, Kite Pharma, and bluebird bio. These companies have launched several CAR T-cell therapy products, such as Kymriah, Yescarta, and Tecartus, which have shown promising results in clinical trials and have received regulatory approval for the treatment of various types of blood cancers. Thus, the market for Chimeric antigen receptor (CAR) T-cell therapy is expected to register a CAGR of 6.9% in the forecast period 2023 to 2033.
Growing demand for personalized and targeted therapies boosting the market growth
The increasing incidence of cancer worldwide is a major driver of the CAR T-cell therapy market. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, with an estimated 9.6 Billion deaths in 2018. CAR T-cell therapy has shown high success rates in clinical trials for the treatment of certain types of blood cancers, such as leukemia and lymphoma. The therapy has demonstrated durable responses and has shown the potential to cure some patients.
CAR T-cell therapy is a personalized and targeted therapy that is tailored to a patient's individual immune system and cancer cells. This approach has gained popularity in recent years as it can result in better outcomes and fewer side effects compared to traditional cancer treatments.
Several biotechnology and pharmaceutical companies are investing heavily in the research and development of CAR T-cell therapies. This has resulted in the development of innovative therapies and the expansion of the CAR T-cell therapy market.
The approval of CAR T-cell therapy products by regulatory agencies, such as the US FDA, has boosted market growth. Regulatory approval provides credibility to CAR T-cell therapy products, which can increase patient and physician acceptance of these therapies.
Active and continuous research and development driving CAR T- cell therapy market growth
CAR T-cell therapy has shown promising results in treating certain types of blood cancers, such as leukemia and lymphoma. However, it is a complex and expensive treatment that requires specialized medical centers with the expertise to perform it. The therapy can also cause severe side effects, including cytokine release syndrome and neurotoxicity, which require careful monitoring and management.
Several companies are actively involved in the development and commercialization of CAR T-cell therapies, including Novartis, Gilead Sciences, Kite Pharma, and bluebird bio. These companies have launched several CAR T-cell therapy products, such as Kymriah, Yescarta, and Tecartus, which have shown promising results in clinical trials and have received regulatory approval for the treatment of various types of blood cancers.
Principal Consultant
The high cost of therapy along with limited availability creates obstacles to market growth
CAR T-cell therapy is a highly expensive treatment due to its complex manufacturing process and personalized nature. The high cost can limit patient access to therapy and can also impact healthcare system budgets. CAR T-cell therapy requires specialized medical centers with the expertise to perform the treatment, which can limit patient access to the therapy. Additionally, the therapy is only approved for the treatment of certain types of blood cancers, which limits its applicability to other cancer types.
CAR T-cell therapy can cause severe side effects, including cytokine release syndrome and neurotoxicity, which can be life-threatening. These side effects require careful monitoring and management, which can add to the overall cost of the therapy.
As the demand for CAR T-cell therapy grows, there is a shortage of manufacturing capacity to produce the therapy at scale. This shortage can limit the availability of the therapy and can also impact the cost of the therapy. The regulatory approval process for CAR T-cell therapy can be challenging and time-consuming. The regulatory agencies require extensive clinical data to support the safety and efficacy of the therapy, which can delay the approval process and increase the overall cost of development.
Availability of advanced healthcare infrastructure shaping landscape for (CAR) T-Cell therapy
North America is a significant market for Chimeric Antigen Receptor (CAR) T-Cell Therapy, with the USA being the largest market in the region. Several factors are driving the growth of the CAR T-cell therapy market in North America, including the high prevalence of cancer, the increasing demand for personalized and targeted therapies, and the availability of advanced healthcare infrastructure. In addition, several biotechnology and pharmaceutical companies in the region are actively involved in the research and development of CAR T-cell therapies, which is driving the growth of the market.
The USA is a key market for CAR T-cell therapy, with several CAR T-cell therapy products approved for the treatment of various types of blood cancers, such as Kymriah, Yescarta, and Breyanzi. The high cost of CAR T-cell therapy in the USA remains a challenge for the market, as it can limit patient access to the therapy. However, initiatives to improve insurance coverage and patient access to CAR T-cell therapy are underway, which is expected to support the growth of the market in the coming years. Thus, North America is expected to possess a 45% market share for (CAR) T-Cell Therapy in 2023.
Increasing demand for effective cancer treatments driving the growth of (the CAR) T-Cell market in Europe
Several factors are driving the growth of the CAR T-cell therapy market in Europe, including the increasing prevalence of cancer, the demand for personalized and targeted therapies, and the availability of advanced healthcare infrastructure. In addition, several biotechnology and pharmaceutical companies in Europe are actively involved in the research and development of CAR T-cell therapies, which is driving the growth of the market.
Several CAR T-cell therapy products have been approved for the treatment of various types of blood cancers in Europe, including Kymriah and Yescarta. The high cost of CAR T-cell therapy remains a challenge for the market in Europe, as it can limit patient access to the therapy. However, initiatives to improve patient access to CAR T-cell therapy are underway, which is expected to support the growth of the market in the coming years.
The European Medicines Agency (EMA) has established a framework for the approval of CAR T-cell therapy products, which is expected to streamline the regulatory process in the future. Overall, the Europe CAR T-cell therapy market is expected to continue to grow in the coming years, driven by the increasing demand for effective cancer treatments and the development of innovative CAR T-cell therapy products. Thus, Europe is expected to possess a 39% market share for (CAR) T-Cell Therapy in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
High rate of positive response contributing to increasing use of (CAR) T-Cell Therapy market
Yescarta is a type of CAR T-cell therapy that involves collecting a patient's T-cells and genetically modifying them in a laboratory to express a chimeric antigen receptor (CAR) that targets a protein called CD19, which is found on the surface of B-cells, including the cancerous B-cells that cause NHL. The modified T-cells are then infused back into the patient, where they seek out and destroy the cancer cells.
Yescarta has been shown to be effective in clinical trials, with high rates of complete response and durable remissions in patients with relapsed or refractory NHL. It is approved by the FDA for use in adults with certain types of NHL and is considered a promising option for patients who have exhausted other treatment options. Thus, by type, Yescarta is expected to possess a 45% market share for (CAR) T-Cell Therapy in 2023.
Key players in the chimeric antigen receptor (CAR) T-Cell therapy market are Abbott Laboratories, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Fresenius SE & Co. KGaA, Johnson & Johnson, Medtronic PLC, Novartis AG, Endo International PLC, and Pfizer Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3.5 billion |
| Market Value in 2033 | US$ 6.82 billion |
| Growth Rate | CAGR of 6.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is valued at US$ 3.5 billion in 2023.
Abbott Laboratories, Baxter International Inc., and Becton, Dickinson, and Company are the leading industry participants.
The market is expected to reach US$ 6.82 billion by 2033.
Rise in cancer cases is propelling the market's growth and development.
The yescarta segment is likely to remain preferred until 2033.
1. Executive Summary | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Abecma 5.3.2. Breyanzi 5.3.3. Kymriah 5.3.4. Tecartus 5.3.5. Yescarta 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Leukemia 6.3.2. Lymphoma 6.3.3. Multiple Myeloma 6.3.4. Autoimmune Disorders 6.3.5. Other Application 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals 7.3.2. Cancer Care Treatment Centers 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. United States of America 9.2.1.2. Canada 9.2.2. By Type 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Type 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. United Kingdom 11.2.1.2. Spain 11.2.1.3. Germany 11.2.1.4. Italy 11.2.1.5. France 11.2.1.6. Rest of Europe 11.2.2. By Type 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. India 12.2.1.4. South Korea 12.2.1.5. Rest of Asia Pacific 12.2.2. By Type 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. South Africa 13.2.1.2. GCC Countries 13.2.1.3. Rest of Middle East and Africa 13.2.2. By Type 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. United States of America 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Type 14.1.2.2. By Application 14.1.2.3. By End User 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Type 14.2.2.2. By Application 14.2.2.3. By End User 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Type 14.3.2.2. By Application 14.3.2.3. By End User 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Type 14.4.2.2. By Application 14.4.2.3. By End User 14.5. United Kingdom 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Type 14.5.2.2. By Application 14.5.2.3. By End User 14.6. Spain 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Type 14.6.2.2. By Application 14.6.2.3. By End User 14.7. Germany 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Type 14.7.2.2. By Application 14.7.2.3. By End User 14.8. Italy 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Type 14.8.2.2. By Application 14.8.2.3. By End User 14.9. France 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Type 14.9.2.2. By Application 14.9.2.3. By End User 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Type 14.10.2.2. By Application 14.10.2.3. By End User 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Type 14.11.2.2. By Application 14.11.2.3. By End User 14.12. India 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Type 14.12.2.2. By Application 14.12.2.3. By End User 14.13. South Korea 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Type 14.13.2.2. By Application 14.13.2.3. By End User 14.14. South Africa 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Type 14.14.2.2. By Application 14.14.2.3. By End User 14.15. GCC Countries 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Type 14.15.2.2. By Application 14.15.2.3. By End User 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Type 15.3.3. By Application 15.3.4. By End User 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Abbott Laboratories 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Baxter International Inc. 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Becton, Dickinson, and Company 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Boston Scientific Corporation 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Fresenius SE & Co. KGaA 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Johnson & Johnson 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Medtronic PLC 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Novartis AG 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Endo International PLC 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Pfizer Inc. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
